相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
DREAMseq (Doublet Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial-ECOG-ACRIN EA6134
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
P. A. Ascierto et al.
ANNALS OF ONCOLOGY (2021)
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
Robert Mason et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
Selma Ugurel et al.
EUROPEAN JOURNAL OF CANCER (2020)
Palliative care in the context of immune and targeted therapies: A qualitative study of bereaved carers' experiences in metastatic melanoma
Jennifer A. Fox et al.
PALLIATIVE MEDICINE (2020)
Optimal treatment strategy for metastatic melanoma patients harboringBRAF-V600mutations
Emilio Francesco Giunta et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
O. Michielin et al.
ANNALS OF ONCOLOGY (2019)
Advances in the systemic treatment of melanoma brain metastases
I. C. Glitza Oliva et al.
ANNALS OF ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B. Johnson et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Biology and treatment of BRAF mutant metastatic melanoma
Benjamin Y. Kong et al.
MELANOMA MANAGEMENT (2016)
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors
Alexander M. Menzies et al.
CANCER (2015)
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Matte S. Cadino et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Outcomes of Patients With Metastatic Melanoma Treated With Immunotherapy Prior to or After BRAF Inhibitors
Allison Ackerman et al.
CANCER (2014)
Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
Paolo Antonio Ascierto et al.
CANCER INVESTIGATION (2014)
分享论文
